AngioDynamics Inc (ANGO) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
AngioDynamics Inc (ANGO) reports robust revenue increases driven by MedTech and NanoKnife segments, despite facing net losses and competitive market pressures. Related Stocks: ANGO
Read the full article2d agoen
You might also wanna read
Baidu Stock Rises 3.2% as Dual-Primary Listing Opens Path to China Investors
GuruFocus·2h ago
SpaceX's $86 Billion IPO Faces Key Starship Test Today
GuruFocus·2h ago
Trump Media (DJT) Launches Truth API for Real-Time Data Access
GuruFocus·2h ago
UnitedHealth Jumps 10.3% After Raising 2026 EPS Outlook Above Estimates
GuruFocus·2h ago
ENR Maintained by JP Morgan -- Price Target Raised to $22
GuruFocus·2h ago
ELF Maintained by JP Morgan -- Price Target Raised to $94
GuruFocus·2h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.